Officials from Hemex Health joined with supportive global health leaders to launch the company’s Gazelle® Diagnostic platform in time for World Sickle Cell Day which fell on Friday, June 19, 2020.
Hemex Health started the development of Gazelle, with technology licensed from Case Western Reserve University. Researcher Dr. Umut Gurkan led studies into the technology in 2014 and said the key is its accessibility. "We now provide an automated analysis of results and interpretation of the results. So this allows the technology to be used by almost anyone,” he said. Underserved areas worldwide will especially benefit.
Clotting disorders, such as Sickle Cell Disease (SCD), are a group of rare genetic blood disorders that cause red blood cells to break down. Patients suffering from SCD have red blood cells that die prematurely, which creates a shortage of healthy red blood cells and can impede blood flow. SCD is a potentially fatal genetically inherited hemoglobin disorder and it is often left undiagnosed and untreated.
The Gazelle® test makes a quick diagnosis using artificial intelligence and microchip technology. Dr. Gurkan says "this is such a special moment for Hemex and CWRU, marking the official launch of a unique product for global health, which will save millions of lives."
'Optimized for the underserved': A new diagnostic test built for low-income settings'
Hemex product page:
Hemex press release:
Dr. Gurkan is the Warren E. Rupp Associate Professor in the Mechanical and Aerospace Engineering Department at Case Western Reserve University. He is leading the CASE Biomanufacturing and Microfabrication Laboratory. Dr. Gurkan is a core investigator at Advanced Platform Technology Center at Louis Stokes Cleveland Veterans Affairs Medical Center.
Dr. Gurkan received a CTSC Annual Pilot award in 2014 to develop this blood assay technology.